Skip Navigation


Annals of Oncology Advance Access originally published online on October 18, 2007
Annals of Oncology 2008 19(1):56-61; doi:10.1093/annonc/mdm434
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/1/56    most recent
mdm434v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gjerde, J.
Right arrow Articles by Lien, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gjerde, J.
Right arrow Articles by Lien, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

breast cancer

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism

J. Gjerde1,2, M. Hauglid2, H. Breilid3,4, S. Lundgren5,6, J. E. Varhaug7, E. R. Kisanga2, G. Mellgren1,2, V. M. Steen3,4 and E. A. Lien1,2,*

1 The Hormone Laboratory, Haukeland University Hospital, N-5021 Bergen
2 Section for Endocrinology, Institute of Medicine, University of Bergen, N-5021 Bergen
3 Dr E. Martens Research Group for Biological Psychiatry, Department of Clinical Medicine, University of Bergen, N-5021 Bergen
4 Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, N-5021 Bergen
5 Cancer Clinic, St Olavs University Hospital, N-7006 Trondheim
6 Department of Cancer Research and Molecular Medicine, Trondheim University Hospital, Norwegian University of Science and Technology, N-7006 Trondheim
7 Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway

* Correspondence to: Dr E. A. Lien, Hormone Laboratory, Haukeland University Hospital, N-5021 Bergen, Norway. Tel: +47-55-97-43-71; Fax: +47-55-97-58-14; E-mail: ernst.lien{at}med.uib.no

Background: Tamoxifen is hydroxylated by cytochrome P450 (CYP) 2D6 to the potent metabolites 4-hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam), which are both conjugated by sulphotransferase (SULT)1A1. Clinical studies indicate that CYP2D6 and SULT1A1 genotypes are predictors for treatment response to tamoxifen. Therefore, we examined the relationship between CYP2D6 genotype, SULT1A1 genotype, SULT1A1 copy number and the pharmacokinetics of tamoxifen.

Patients and methods: The serum levels of tamoxifen and metabolites of 151 breast cancer patients were measured by high-pressure liquid chromatography–tandem mass spectrometry. The CYP2D6 and SULT1A1 polymorphisms and SULT1A1 copy number were determined by long PCR, PCR-based restriction fragment length polymorphism, DNA sequencing and fluorescence-based PCR.

Results: The levels of 4OHtam, 4OHNDtam and N-demethyltamoxifen were associated with CYP2D6 predicted enzymatic activity (P < 0.05). The SULT1A1 genotype or copy number did not influence the levels of tamoxifen and its metabolites. However, the ratios of N-demethyltamoxifen/tamoxifen and N-dedimethyltamoxifen/N-demethyltamoxifen were related to SULT1A1 genotype.

Conclusion: CYP2D6 and SULT1A1 genotypes may partly explain the wide inter-individual variations in the serum levels of tamoxifen and its metabolites. We propose that therapeutic drug monitoring should be included in studies linking CYP2D6 and SULT1A1 genotypes to clinical outcome.

Key words: breast cancer, CYP2D6, endoxifen, 4-OH-N-demethyltamoxifen, SULT1A1, tamoxifen

Received for publication July 5, 2007. Accepted for publication July 26, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. P. Goetz, V. J. Suman, F. J. Couch, M. M. Ames, J. M. Rae, M. G. Erlander, X.-J. Ma, D. C. Sgroi, C. A. Reynolds, W. L. Lingle, et al.
Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance
Clin. Cancer Res., September 15, 2008; 14(18): 5864 - 5868.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.